

Contents

About the authors	xv
Contributors	xvii
Acknowledgements	xix
Introduction	xxi
Part 1 Product eligibility	1
Chapter 1 Classification of herbal (medicinal) products	3
Introduction	3
Classification as a medicine	4
Herbal medicinal products (HMPs)	5
How herbal medicines can reach the market	5
Unlicensed herbal remedies	5
Registered traditional herbal medicines	5
Licensed herbal medicines	6
Traditional herbal medicinal product (THMP)	6
Committee on Herbal Medicinal Products (HMPC)	6
Herbal Medicinal Products Working Party (HMPWP)	8
Monoproducts	9
Combinations	9
Minus variants	9
Products with a well-established medicinal use (WEU)	10
Alternative marketing opportunities	11
Foods, food (dietary) supplements and novel food	11
Food	11
Food supplements	12
Genetically modified (GM) and novel foods	14
Cosmetics	14
Borderline products	15
How to determine whether a product is medicinal	15
Pharmacological action	16
Immunological action	17
Metabolic action	17

Summary	17
THMP	18
WEU	18
Full marketing authorisation	18
Food/food supplement	18
Cosmetic	18
References	19
Part 2 Content and presentation	21
Chapter 2 Proof of tradition	23
Introduction	23
The EU – regions	25
EU member states	25
Outermost regions	25
Overseas countries and territories	25
Special territories	25
Sources for information on traditional use	26
Commission E	26
Commission E monographs	26
ESCOP	27
SPC	27
ESCOP monographs	28
WHO	28
WHO monographs	29
EMA/Committee on Herbal Medicinal Products (HMPC) and Working Party on Community Monographs and Community List (MLWP)	29
EMA	29
HMPC	30
MLWP	30
Community monographs	30
<i>British Herbal Pharmacopoeia</i> (BHP)	31
BHP monographs	32
Other sources of evidence for traditional use	32
<i>Martindale</i> , Rote Liste and other product listings, GSL	32
<i>European Pharmacopoeia</i>	33
Other pharmacopoeias	33
Standard textbooks	34
MHRA <i>Herbal Ingredients and Uses</i> (2005)	35
Journals, databases and other online sources	35
Libraries, archives and collections	36
Societies and associations	36
References	37
Chapter 3 Common technical document	39
Introduction	40
Pyramid chart	40
Module 1	40
Module 2	40

Module 3	41
Module 4	42
Module 5	42
<i>Module 1: European Union (EU) administrative information and prescribing information</i>	44
1.0 Cover letter	44
1.1 Comprehensive table of contents	44
1.2 Application form	46
1.3 Product information	46
1.3.1 SPC, labelling and package leaflet	46
1.3.2 Mock-up	46
1.3.3 Specimen	47
1.3.4 Consultation with target patient groups	47
1.3.5 Product information already approved in the member states (where applicable)	47
1.3.6 Braille	47
1.4 Information about the experts	47
1.4.1 Quality	48
1.4.2 Non-clinical	48
1.4.3 Clinical	48
1.5 Specific requirements for different types of applications	49
1.6 Environmental risk assessment	49
1.7 Information relating to orphan-market exclusivity	49
1.8 Information relating to pharmacovigilance	49
1.9 Information relating to clinical trials	49
Additional data	49
<i>Module 2: Common technical document summaries</i>	49
2.1 Common technical document table of contents (modules 2–5)	49
2.2 Introduction	50
2.3 Quality overall summary	50
Introduction	50
2.3.S Drug substance (name, manufacturer)	50
2.3.P Drug product (name, dosage form)	51
2.3.A Appendices	52
2.3.R Regional information	52
2.4 Non-clinical overview	53
2.5 Clinical overview	54
2.6 Non-clinical summary	54
2.7 Clinical summary	55
<i>Module 3: Quality – chemical, pharmaceutical and biological information for chemical active substances and biological medicinal products</i>	55
3.1 Table of contents of Module 3	55
3.2 Body of data	55
3.2.S Drug substance (name, manufacturer)	55
3.2.P Drug product (name, dosage form)	58
3.2.A Appendices	62
Literature references	62

<i>Module 4: Non-clinical study reports</i>	62
4.1 Table of contents	62
4.2 Study reports	62
4.3 Literature references	62
<i>Module 5: Clinical study reports</i>	63
5.1 Table of contents	63
5.2 Tabular listing of all clinical studies	63
5.3 Clinical study reports	63
5.4 Literature references	63
Appendices	63
Table of contents formatting	63
Module 2	63
Module 3	63
References	64
Chapter 4 Good agricultural and collection practice	65
Introduction	65
General definition of good agricultural and collection practices	66
Benefits of GACP	68
Benefits to suppliers	68
Benefits to buyers	68
EMEA/HMP/31/99/Rev.3 – document	69
General	69
Quality assurance	69
Personnel and education	69
Documentation	70
Seeds and propagation material	70
Cultivation	70
Standardisation of product	71
Soil and fertilisation	71
Heavy metals	71
Irrigation	72
Crop maintenance and plant protection	72
Collection	73
Harvesting	73
Drying and primary processing	73
Packaging	74
Storage, transport and distribution	74
Contaminants and adulteration	74
Microbiological contamination	75
Mycotoxins	75
The safety of herbs	75
Conservation and sustainability	76
Environmental impact	77
CITES	78
Conservation in the UK	79
Ethical standards and social responsibility issues	79
Intellectual property rights	80
References	80
Web references	81

Chapter 5	Quality requirements for traditional herbal medicinal products	83
	Introduction	83
	Special issues and challenges when evaluating herbal products	84
	Definition and legal basis	84
	General aspects of quality assurance and quality control of herbal (medicinal) products	86
	Purpose of quality assurance/quality control of herbals	86
	Methods and monographs	86
	Identity	88
	Chemical constituents and markers	88
	Purity	89
	Assay	90
	Reference standards	90
	Validation	91
	Stability testing	92
	Labelling	93
	Quality requirements and methods	94
	Drug	94
	Herbal preparation	95
	Finished product	99
	Solid oral forms for single-dose application (tablets, capsules)	100
	Oral liquids	101
	Batch-to-batch consistency	101
	Definitions and glossary	102
	Checklist: quality requirements for a licence application	104
	Checklist: definition of raw material/quality (DCL 2)	104
	Checklist: raw material pre-check for further supply and testing (DCL 3)	105
	Checklist: definition of extract quality (DCL 4)	105
	Checklist: extract material pre-check for further supply and testing (DCL 5)	106
	Checklist: definition of quality of the finished product (DCL 6)	107
	Checklist: finished product pre-check for further supply and testing (DCL 7)	107
	General addendum (for all checklists)	108
	Stability tests	108
	References	113
Chapter 6	Safety and pharmacovigilance	115
	Introduction	115
	Non-clinical overview	116
	Pharmacology	116
	Safety pharmacology	116
	Pharmacodynamic drug interactions	116
	Pharmacokinetics	117
	Pharmacokinetic drug interactions	117
	Toxicology	118
	Single- and repeated-dose toxicity	118
	Genotoxicity	118
	Carcinogenicity	120
	Reproductive and developmental toxicity	121
	Local tolerance and other toxicity studies	122
	Phototoxicity	122
	CTD non-clinical overview	122

Clinical overview	123
Clinical pharmacology	123
Common adverse events	124
Poisoning/overdose	124
Hypersensitivity and allergenicity	124
Hepatotoxicity	125
Herb–drug interactions	125
Pregnancy and lactation	126
Periodic Safety Update Reports (PSUR)	127
Summary and conclusion	127
References	128
Chapter 7 Labelling	131
Introduction	132
The directives	132
Explanation of the terms in the directives	133
Article 11 and 16(c): summary of product characteristics	133
Article 16(g) (1)	133
Article 16(g) (2)	134
Summary of product characteristics	134
The role of the SmPC	134
The content of the SmPC	135
Requirements for the SmPC	135
1 Name of the medicinal product	136
2 Qualitative and quantitative composition	136
3 Pharmaceutical form	136
4 Clinical particulars	136
5 Pharmacological properties	138
6 Pharmaeutical particulars	139
7 Marketing authorisation holder	140
8 Marketing authorisation number(s)	140
9 Date of first authorisation/renewal of the authorisation	140
10 Date of revision of the text	140
SmPC fragments	140
Examples of an SmPC	140
1 Name of the medicinal product	140
2 Qualitative and quantitative composition	140
3 Pharmaceutical form	141
4 Clinical particulars	141
5 Pharmacological properties	142
6 Pharmaeutical particulars	142
7 Marketing authorisation holder	142
8 Marketing authorisation number(s)	142
9 Date of first authorisation/renewal of the authorisation	142
10 Date of revision of the text	142
Requirements for packaging components	145
Basic requirements for packaging	146
Requirements for packaging of blister packs	147
Requirements for packaging of small containers	147

Braille requirements for packaging	147
Design and layout of packaging components	148
Artwork mock-ups	148
Examples of packaging components	148
Requirements for package leaflets	148
Basic requirements for package leaflets	150
Requirements for package leaflets for blind or partially sighted people	152
Artwork mock-ups	152
Example of package leaflets	152
User testing of package leaflets	152
Introduction	152
The directives	152
Explanation of the terms in the directives	155
Hints for writing a package leaflet that will pass a user test	155
Hints for writing style	156
Hints for a good layout	156
Things to remember	156
What is user testing?	157
Outline of user testing	158
Points to remember when carrying out user testing	158
Examples of writing patient-friendly leaflets	159
SmPC statements	159
Package leaflet statements	160
Bridging user testing	161
Examples of patient-friendly leaflets	161
Conclusion	161
References	168
Directives	168
Consolidated code	168
Guidelines	168
Other	169
Part 3 The practicalities	171
Chapter 8 Submission of THM registration applications — frequently asked questions	173
Introduction	173
Is there any guidance available?	174
What are the prerequisites for submitting an application?	174
Manufacturers and importers	174
Wholesale dealers	174
Registration with the MHRA and obtaining traditional herbal registration (THR)	174
Do I need an in-house qualified person (QP)?	175
What are the registration application fees and when and how do I pay?	175
Fees	175
Standard	175
Reduced	175
Complex	176

Easement of payment	176
Bank details for payment by bank transfer	176
How do I fill in the application form?	177
Do I submit on paper or electronically?	181
What are the formal requirements for my dossier?	181
Structure and file format	181
File names	182
Disk labelling	182
Where do I submit?	183
Whom do I ask for further guidance?	183
What happens next?	183
References	184
Part 4 Appendices	185
Appendix 1 MHRA documents	187
1.1 Additional requirements for applicants for a new wholesale dealer's licence for human use	188
1.2 Herbal or homeopathic registration application	190
1.3 Best practice guidance on labelling and packaging of medicines	211
1.4 Guidance for the pharmaceutical industry on the use of bridging studies	220
1.5 Summary of product characteristics	227
1.6 GSL List B: Consolidated list of substances which are present in authorised medicines for general use	228
1.7 Guidance concerning the Braille requirements for labelling and the packaging leaflet	268
1.8 Herbal ingredients and uses 2005	272
1.9 Herbal or homeopathic registration application	284
1.10 Application form for manufacturer's importer's licence (MIA)	305
1.11 Notes for applicants and holders of a manufacturer's licence	335
1.12 Notes for applicants and holders of a wholesale dealer's licence	365
1.13 Traditional Herbal Medicinal Product Directive: transitional qualified persons	396
1.14 Guidance on the user testing of patient information leaflets	397
1.15 Application form for a wholesale dealer's licence	403
Appendix 2 EU—EMEA documents	417
2.1 CHMP guideline on excipients in the dossier for application for marketing authorisation of a medical product	418
2.2 Note for guidance on bracketing and matrixing designs for stability testing of drug substances and drug products	430
2.3 CPMP guideline on stability testing: stability testing of existing active substances and related finished products	438
2.4 CHMP guideline on declaration of storage conditions	456
2.5 CHMP/CVMP guideline on quality of herbal medicinal products/traditional herbal medicinal products	460
2.6 CHMP/CVMP guideline on specifications: test procedures and acceptance criteria for herbal substances, herbal preparations and herbal medicinal products/traditional herbal medicinal products	471

2.7	Directive 2001/83/EC	492
2.8	Directive 2004/24/EC	554
2.9	Directive 2001/83/EC	560
2.10	HMPC guideline on non-clinical documentation for herbal medicinal products in applications for marketing authorisation (bibliographical and mixed applications) and in applications for simplified registration	625
2.11	HMPC guideline on the clinical assessment of fixed combinations of herbal substances/herbal preparations	632
2.12	HMPC overview of status of HMPC assessment work	638
2.13	HMPC draft concept paper on the development of a guideline on the assessment of genotoxic constituents in herbal substances/preparations	642
2.14	HMPC guideline on good agricultural and collection practice (GACP) for starting materials of herbal origin	646
2.15	HMPC/CHMP/CVMP guideline on quality of combination herbal medicinal products/traditional herbal medicinal products	657
2.16	HMPC/CHMP/CVMP guideline on declaration of herbal substances and herbal preparations in herbal medicinal products/traditional herbal medicinal products in the SPC	668
2.17	Annex I Summary of product characteristics	683
Appendix 3	PhEur documents	709
3.1	Capsules	710
3.2	Semi-solid rectal preparations for cutaneous applications	712
3.3	Tablets	714
3.4	Liquid preparations for oral use	717
3.5	Extracts	719
3.6	Liquid preparations for cutaneous applications	722
3.7	Herbal drug preparations	724
3.8	Herbal drug preparations	726
3.9	Herbal teas	727
3.10	Products of fermentation	728
3.11	Essential oils	730
Appendix 4	Commission E monographs	733
4.1	Commission E monographs	734
4.2	European Scientific Cooperative on Phytotherapy (ESCOP) monographs	739
4.3	World Health Organization (WHO) monographs	740
4.4	<i>British Herbal Pharmacopoeia</i> (BHP) monographs	741
4.5	Herbal monographs contained in the 6th edition of the <i>European Pharmacopoeia</i>	744
4.6	Organisation of the Common Technical Document	746
4.7	Pesticide residues – acceptable limits	749
4.8	Examples of potential adverse effects of herbal ingredients	750
4.9	List of herbals best avoided or used with caution during pregnancy	752
4.10	List of medicinal plants protected under Convention on International Trade in Endangered Species of wild fauna and flora (CITES)	
	Appendix 2	754
	Index	755